Breaking News: Myriad Genetics Acquires Gateway Genomics | Learn More
Chair of the Board
S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009, held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007. She was President, Specialty Products which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries. Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance. Ms. Phanstiel’s life science experience includes having previously served on the Board of Directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc.
Paul Bisaro is an experienced global business leader with almost 30 years of pharmaceutical experience and has a track record of driving company growth through operational execution and corporate transformation. He has served as Chief Executive Officer as well as Executive Chairman of numerous companies including Watson Pharmaceuticals, Actavis plc, Allergan plc, Impax Laboratories and Amneal Pharmaceuticals. Mr. Bisaro also served as Chief Operations Officer and General Counsel of Barr Laboratories.
In addition to his service on the Board of Myriad, Mr. Bisaro serves as Chairman of the Board of Mallinckrodt, PLC and is currently on the Board of Zoetis, Inc. (NYSE:ZTS) and TherapeuticsMD (NASDAQ:TXMD). Since 2014, Mr. Bisaro has been a Member of the Board of Visitors of the Catholic University of America’s Columbus School of Law. He also served as Chairman of the Board of the Generic Pharmaceutical Association (GPhA, now the Association of Accessible Medicines) in 2010 and 2011. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan (1983) and a Juris Doctor from Catholic University of America in Washington, D.C. (1989).
President and CEO, Myriad Genetics, Inc.
Paul J. Diaz, was named president, chief executive officer and member of the Myriad Genetics board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses.
Paul is the former president and chief executive officer and vice chairman of Kindred Healthcare, Inc. (NYSE:KND) (2002-2016) a Fortune 500 Company and one of the largest providers of healthcare services in the United States. At the time, Kindred had revenues of $7.2 billion, rehabilitation hospitals, sub-acute units, home health and hospice agencies and contract rehabilitation locations. For six years in a row, during his tenure as CEO, Kindred was ranked one of the Most Admired healthcare companies in the U.S. by Fortune magazine.
Paul currently serves on the board of directors of DaVita (NYSE: DVA), the board of trustees of Johns Hopkins Medicine (where he serves as chair of Johns Hopkins Healthcare), and the board of visitors of the Georgetown University Law Center. He was formerly on the board of directors of PharMerica Corporation (NYSE: PMC), and previously served on the board of the federation of American Hospitals, and the Bloomberg School of Public Health at John Hopkins University. While chief executive officer of Kindred, Paul was a member of the Business Roundtable and the Wall Street Journal CEO Council. Modern Healthcare magazine named Paul one of the 100 Most Influential People in Healthcare and named him one of the top 25 Minority Executives in Healthcare for numerous years. In addition, Hispanic magazine named Paul one of the 25 Best Latinos in business in multiple years. Paul earned a bachelor’s degree in Finance and Accounting from American University’s Kogod School of Business and a law degree from Georgetown University Law Center in Washington, D.C.
Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
Rashmi Kumar was named a Director of Myriad Genetics in September 2020. Currently, she serves as Senior Vice President and Chief Information Officer, Global IT, at Hewlett Packard Enterprise. Prior to that, she was SVP and CIO, U.S Pharmaceutical, at McKesson and served in senior leadership roles for large enterprises including Southern California Edison, Toyota, and Tata Steel. She earned a Bachelor’s degree in metallurgical engineering from Bihar Institute of Technology in Sindri, India and a M.B.A. from University of California, Irvine’s Paul Merage School of Business.
Lee N. Newcomer, M.D., board-certified medical oncologist, joined the company in September 2019. Most recently, he was Senior Vice President of Oncology and Genetics for UnitedHealthcare. Previously, he served as Chief Medical Officer and Senior Vice President of Health Policy and Strategy at UnitedHealth Group, and Chief Medical Officer at Vivius, Inc. Dr. Newcomer earned a M.D. from University of Nebraska College of Medicine, a M.H.A from University of Wisconsin-Madison and a B.A. from Nebraska Wesleyan.
Colleen F. Reitan joined the company in September 2019. Most recently, she served as President of Plan Operations for Healthcare Service Corporation (HCSC). Prior to that, she held several roles, including serving as the Executive Vice President and Chief Operating Officer of HCSC and President and Chief Operating Officer of Blue Cross & Blue Shield of Minnesota. She previously served on boards at Availity LLC, MEDecision, Inc. and Prime Therapeutics LLC. Reitan has a M.H.A. from the University of Minnesota and a B.A. in Urban Studies and Economics from Minnesota State University.
Daniel M. Skovronsky, M.D., Ph.D., joined the company as a Director in July 2020. Currently, he serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. Previously, he was Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine, University of Pennsylvania, his Ph.D. in neuroscience from University of Pennsylvania and a B.S. in molecular biophysics and biochemistry from Yale University.
Daniel K. Spiegelman has been a Director of the company since May 2020. Most recently, he served as Executive Vice President and Chief Financial Officer at BioMarin Pharmaceuticals, Inc. Prior to that, he held several roles, including Senior Vice President and Chief Financial Officer of CV Therapeutics and Treasurer at Genentech, Inc. He is currently a member of the board of directors at Tizona Therapeutics, Inc., a private pharmaceutical company. Mr. Spiegelman received a B.A. degree from Stanford University and a M.B.A. from the Stanford Graduate School of Business.